BRPI0408946A - material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo - Google Patents

material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo

Info

Publication number
BRPI0408946A
BRPI0408946A BRPI0408946-4A BRPI0408946A BRPI0408946A BR PI0408946 A BRPI0408946 A BR PI0408946A BR PI0408946 A BRPI0408946 A BR PI0408946A BR PI0408946 A BRPI0408946 A BR PI0408946A
Authority
BR
Brazil
Prior art keywords
biologically active
biocompatible polymer
pharmaceutical composition
active material
same
Prior art date
Application number
BRPI0408946-4A
Other languages
English (en)
Inventor
Myung-Ok Park
Original Assignee
Biopolymed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040007983A external-priority patent/KR20040086521A/ko
Application filed by Biopolymed Inc filed Critical Biopolymed Inc
Publication of BRPI0408946A publication Critical patent/BRPI0408946A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MATERIAL BIOLOGICAMENTE ATIVO CONJUGADO COM POLìMERO BIOCOMPATìVEL COM COMPLEXO 1:1, SEU PROCESSO DE PREPARAçãO E COMPOSIçãO FARMACêUTICA COMPREENDENDO O MESMO". A presente invenção refere-se a conjugados de polímeros biocompatíveis e moléculas biologicamente ativas onde o polímero biocompatível ativado está conjugado a um grupo carboxila de material biologicamente ativo em uma razão molar de 1:1 e processos de sua preparação e uma composição farmacêutica compreendendo os mesmos.
BRPI0408946-4A 2003-03-28 2004-03-27 material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo BRPI0408946A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20030019734 2003-03-28
KR1020040007983A KR20040086521A (ko) 2003-03-28 2004-02-06 생물학적 활성물질과 생체적합성 고분자의 1:1 접합체,이의 제조방법과 이를 함유하는 약학 조성물
PCT/KR2004/000701 WO2004084948A1 (en) 2003-03-28 2004-03-27 Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
BRPI0408946A true BRPI0408946A (pt) 2006-04-04

Family

ID=36118393

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408946-4A BRPI0408946A (pt) 2003-03-28 2004-03-27 material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo

Country Status (8)

Country Link
US (2) US20050059129A1 (pt)
EP (1) EP1608408A4 (pt)
JP (1) JP2006521372A (pt)
AU (1) AU2004224466B2 (pt)
BR (1) BRPI0408946A (pt)
CA (1) CA2530725A1 (pt)
MX (1) MXPA05010411A (pt)
WO (1) WO2004084948A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US7786213B2 (en) * 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
KR100759130B1 (ko) * 2005-02-12 2007-09-19 휴메드 주식회사 항 인테그린 항체 코팅스텐트 및 그의 제조방법
JP5258756B2 (ja) * 2006-05-17 2013-08-07 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー パーソナルケア組成物
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
KR20100052730A (ko) * 2008-11-11 2010-05-20 한국유니온제약 주식회사 생체적합성 고분자와 결합한 신규한 에리스로포이에틴 접합체
SG179131A1 (en) * 2009-09-15 2012-04-27 Kaneka Corp Modified erythropoietin to which water-soluble long-chain molecule is added
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA023360B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5597709A (en) * 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
EP1477496A4 (en) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG-CONJUGATED PTH BZW. PEG-CONJUGATED PTH DERIVATIVE
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
WO2004076474A2 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
WO2005067454A2 (en) * 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Combination therapy for treating hepatitis c virus infection

Also Published As

Publication number Publication date
MXPA05010411A (es) 2006-05-31
WO2004084948A1 (en) 2004-10-07
CA2530725A1 (en) 2004-10-07
US20070117924A1 (en) 2007-05-24
EP1608408A1 (en) 2005-12-28
US20050059129A1 (en) 2005-03-17
AU2004224466A1 (en) 2004-10-07
JP2006521372A (ja) 2006-09-21
EP1608408A4 (en) 2008-02-27
AU2004224466B2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
Shahzadi et al. Arginine-based cationic surfactants: Biodegradable auxiliary agents for the formation of hydrophobic ion pairs with hydrophilic macromolecular drugs
BR9903345A (pt) Emplastro cosmético, farmacêutico ou dermatológico e conjunto
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0613005A8 (pt) uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ATE288256T1 (de) Dermale zusammensetzungen
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
WO2004060405A3 (en) Tissue reactive compounds and compositions and uses thereof
GEP20022804B (en) Erythropoietin Derivatives
ATE252601T1 (de) Lang wirkende insulinotrope peptide
ATE369878T1 (de) Träger-pharmaka-konjugate
BR0208338A (pt) Derivados de piridina
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0307893A (pt) Formulação oftálmica com sistema de goma
GEP20063917B (en) Pulmonary administration of chemically modified insulin
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
BRPI0309868B1 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
BRPI0417341A (pt) fator ix glicopeguilado
EP0787009A4 (en) CANCER-INHIBITING PEPTIDES
TR201907313T4 (tr) İki PEG zinciri içeren PEG türevleri.
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BRPI0518050A (pt) composição para debridamento a partir da bromelina e métodos para produção da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01)